

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Elazar Rabbani et al  
Serial No. 08/978,632  
Filed: November 25, 1992  
Title: NOVEL PROPERTY EFFECTING  
AND/OR PROPERTY EXHIBITING  
COMPOSITIONS FOR THERAPEUTIC  
AND DIAGNOSTIC USE



Group Art Unit: 1635

Examiner: Mary M. Schmidt

527 Madison Avenue, 9th Floor  
New York, New York 10022  
August 3, 1999

Honorable Commissioner  
of Patents and Trademarks  
Washington, D.C. 20231

DECLARATION UNDER 37 C.F.R. §1.821(g)


Dear Sirs:

RONALD C. FEDUS hereby declares as follows:

1. I am the attorney in charge of the above-identified application, and I am fully familiar with its content.
2. I have compared the information transmitted via seq id nos: 1-51 as per the paper copy submitted with the accompanying Second Communication, and attest that they present no new matter.
3. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of title 18 of the United States code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

August 3, 1999

Date

  
Ronald C. Fedus  
Registration No. 32,567  
Attorney for Applicants


ENZO THERAPEUTICS, INC.  
c/o Enzo Biochem, Inc.  
527 Madison Avenue (9<sup>th</sup> Fl.)  
New York, New York 10022  
(212) 583-0100

LC/USProsecution/Enz53Crdf dec under 37 cfr1.821g re sequences.073099enz53C

ENZ-53(C)

FIRST CLASS CERTIFICATE

I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as first class mail in an envelope addressed to:  
Commissioner of Patents & Trademarks Washington,  
D.C. 20231

  
Ronald C. Fedus  
Reg. No. 32,567

AUG 3 99  
Date

Elazar Rabbani et al.  
Serial No. 08/978,632  
Filed: November 25, 1997  
Page 2 (Second Communication Directed to Notice to Comply With Sequence Rules  
August 3, 1999)

4. a Declaration Under 37 C.F.R. §1.821(g) attesting that the content of the substitute paper and substitute computer readable copies are the same and include no new matter.

No fee is believed due in connection with this Communication or the documents or items submitted herewith. If any other fee or fees are due, however, the Patent and Trademark Office is hereby authorized to charge the amount of any such fee to Deposit Account 05-1135, or to credit any overpayment thereto.

If helpful to processing this Communication, the undersigned may be contacted by telephone at (212) 583-0100 during the daytime hours.

Respectfully submitted,



Ronald C. Fedus  
Registration No. 32,567  
Attorney for Applicants

ENZO THERAPEUTICS, INC.  
c/o Enzo Biochem, Inc.  
527 Madison Avenue (9<sup>th</sup> Fl.)  
New York, New York 10022  
(212) 583-0100

LC/USProsecution/Enz53(C/2ndcommunication.re.sequence rules073099.enz53(c)

ENZ-53(C)